ANI Pharmaceuticals | ANIP - Interest Expense On Debt


ANI Pharmaceuticals reported $4.41M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
AbbVie USD 740M 40M Jun/2025
ANI Pharmaceuticals USD 4.41M 316K Dec/2025
Assertio Holdings USD 758K 1000 Jun/2024
Aurora Cannabis CAD 2.11M 116K Dec/2025
Canopy Growth CAD 7.34M 1.46M Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Heron Therapeutics USD 600K 100K Dec/2024
Hikma Pharmaceutical USD 67M 47M Dec/2025
Knight Therapeutics CAD 3.92M 1.56M Dec/2025
Nektar Therapeutics USD 9.77M 3.75M Dec/2025
Novartis USD 281M 8M Sep/2025
Omeros USD 4.05M 5.16M Sep/2024
Perrigo USD 10.08B 10.04B Sep/2025
Sun Pharmaceuticals INR 998.6M 250.6M Sep/2025
Teva Pharmaceutical Industries USD 220M 17M Dec/2025